<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232492</url>
  </required_header>
  <id_info>
    <org_study_id>DOK-015</org_study_id>
    <nct_id>NCT00232492</nct_id>
  </id_info>
  <brief_title>Ketamine on Acute Pain in Females and Males</brief_title>
  <official_title>Effect of Racemic Ketamine on Pain in Females and Males After Surgical Removal of Third Molars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether equal subanesthetic doses of racemic
      ketamine is equally effective on females and males after surgical removal of third molars
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ketamine is assumed to be a NMDA receptor antagonist which provides analgesia from acute
      postoperative pain(and other types of pain) subanesthetic doses. Gender differences in
      ketamine analgesia are not known. This placebo-controlled,randomised, parallel group study
      investigates the analgesic dose-response effect of ketamine in subanesthetic doses in female
      and male patients following surgical removal of third molars.

      Comparisons: Placebo and ketamine in females and males.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum pain NRS</measure>
    <time_frame>60 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Several subjective variables assessing psychotomimetic effects</measure>
    <time_frame>0, 15, 60</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Mouth and Tooth Diseases</condition>
  <condition>Tooth, Impacted</condition>
  <arm_group>
    <arm_group_label>Placebo males</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline physiological placebo males</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0,1 mg/kg males</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0,1 mg/kg ketamine males</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0,3 mg/kg males</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0,3 mg/kg ketamine males</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0,5 mg/kg males</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0,5 mg/kg ketamine males</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo females</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline physiological as placebo females</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.1 mg/kg females</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0,1 mg/kg ketamine females</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0,3 mg/kg females</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0,3 mg/kg ketamine females</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0,5 mg/kg females</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0,5 mg/kg ketamine females</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo males</intervention_name>
    <description>Intravenous saline bolus (Placebo-control) males</description>
    <arm_group_label>Placebo males</arm_group_label>
    <other_name>saline physiological 5 ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0,1 mg/kg males</intervention_name>
    <description>0,1 mg/kg ketamine iv bolus males</description>
    <arm_group_label>Ketamine 0,1 mg/kg males</arm_group_label>
    <other_name>Ketalar ATC-nr.: N01A X03</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0,3 mg/kg males</intervention_name>
    <description>0,3 mg/kg ketamine iv bolus males</description>
    <arm_group_label>Ketamine 0,3 mg/kg males</arm_group_label>
    <other_name>Ketalar ATC-nr.: N01A X03</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0,5 mg/kg males</intervention_name>
    <description>0,5 mg/kg ketamine iv bolus males</description>
    <arm_group_label>Ketamine 0,5 mg/kg males</arm_group_label>
    <other_name>Ketalar ATC-nr.: N01A X03</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo females</intervention_name>
    <description>Intravenous saline bolus (Placebo-control) females</description>
    <arm_group_label>Placebo females</arm_group_label>
    <other_name>Saline physiological 5 ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0,1 mg/kg females</intervention_name>
    <description>0,1 mg/kg iv bolus ketamine females</description>
    <arm_group_label>Ketamine 0.1 mg/kg females</arm_group_label>
    <other_name>Ketalar ATC-nr.: N01A X03</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0,3 mg/kg females</intervention_name>
    <description>0,3 mg/kg iv bolus ketamine females</description>
    <arm_group_label>Ketamine 0,3 mg/kg females</arm_group_label>
    <other_name>Ketalar ATC-nr.: N01A X03</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0,5 mg/kg females</intervention_name>
    <description>0,5 mg/kg iv bolus ketamine females</description>
    <arm_group_label>Ketamine 0,5 mg/kg females</arm_group_label>
    <other_name>Ketalar ATC-nr.: N01A X03</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for removal of third molar

          -  Between 20 and 30 years of age

          -  ASA Class 1

        Exclusion Criteria:

          -  Psychiatric family (father/mother) or own anamnestic history

          -  Hypersensitivity towards NSAIDS or other rescue analgesics

          -  Verified or suspected pregnancy

          -  Lactating females

          -  Surgery lasting over 60 min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lasse A Skoglund, DDS, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Section of Dental Pharmacology and Pharmacotherapy, Faculty of Dentistry, POB 1119 Blindern, University of Oslo, N-0317 Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olav Hustveit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section of Dental Pharmacology and Pharmacotherapy, Faculty of Dentistry, POB 1119 Blindern, University of Oslo, N-0317 Oslo, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oral and Maxillofacial Surgery, Ullevaal University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Oye I, Mathisen LC. The effect of CPP in neurogenic pain: inhibition of spinal or cortical NMDA receptors? Pain. 1993 Jun;53(3):358-60.</citation>
    <PMID>8351166</PMID>
  </reference>
  <reference>
    <citation>Ã˜ye I, Hustveit O, Maurset A, Ratti Moberg E, Paulsen O, Skoglund LA. The chiral forms of ketamine as probes for NMDA receptor functions in humans. In: NMDA receptor related agents: Biochemistry, pharmacology and behaviour. Kameyama T, Domino E (eds). NPP Books, Ann Arbor, 1991.</citation>
  </reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2005</study_first_submitted>
  <study_first_submitted_qc>October 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <last_update_submitted>July 3, 2011</last_update_submitted>
  <last_update_submitted_qc>July 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Professor Lasse A. Skoglund</name_title>
    <organization>Section of Dental Pharmacology and Pharmacotherapy, University of Oslo, Norway</organization>
  </responsible_party>
  <keyword>Wisdom</keyword>
  <keyword>Tooth</keyword>
  <keyword>Teeth</keyword>
  <keyword>Third</keyword>
  <keyword>Molar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Diseases</mesh_term>
    <mesh_term>Tooth, Impacted</mesh_term>
    <mesh_term>Stomatognathic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

